Annual Cash & Cash Equivalents
$4.20 M
-$1.15 M-21.48%
December 31, 2023
Summary
- As of February 21, 2025, LIXT annual cash & cash equivalents is $4.20 million, with the most recent change of -$1.15 million (-21.48%) on December 31, 2023.
- During the last 3 years, LIXT annual cash & cash equivalents has fallen by -$865.80 thousand (-17.08%).
- LIXT annual cash & cash equivalents is now -21.48% below its all-time high of $5.35 million, reached on December 31, 2022.
Performance
LIXT Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$1.64 M
-$957.60 K-36.90%
September 30, 2024
Summary
- As of February 21, 2025, LIXT quarterly cash and cash equivalents is $1.64 million, with the most recent change of -$957.60 thousand (-36.90%) on September 30, 2024.
- Over the past year, LIXT quarterly cash and cash equivalents has dropped by -$957.60 thousand (-36.90%).
- LIXT quarterly cash and cash equivalents is now -78.84% below its all-time high of $7.74 million, reached on March 31, 2021.
Performance
LIXT Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
LIXT Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -21.5% | -36.9% |
| 3 y3 years | -17.1% | -43.8% |
| 5 y5 years | -1.6% | -43.8% |
LIXT Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -21.5% | at low | -78.8% | at low |
| 5 y | 5-year | -21.5% | +61.7% | -78.8% | +52.2% |
| alltime | all time | -21.5% | >+9999.0% | -78.8% | >+9999.0% |
Lixte Biotechnology Holdings Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $1.64 M(-36.9%) |
| Jun 2024 | - | $2.60 M(-24.0%) |
| Mar 2024 | - | $3.41 M(-18.8%) |
| Dec 2023 | $4.20 M(-21.5%) | $4.20 M(-17.7%) |
| Sep 2023 | - | $5.11 M(+75.3%) |
| Jun 2023 | - | $2.91 M(-28.8%) |
| Mar 2023 | - | $4.09 M(-23.6%) |
| Dec 2022 | $5.35 M(+11.0%) | $5.35 M(-18.4%) |
| Sep 2022 | - | $6.56 M(-15.2%) |
| Jun 2022 | - | $7.74 M(+104.8%) |
| Mar 2022 | - | $3.78 M(-21.7%) |
| Dec 2021 | $4.82 M(-4.8%) | $4.82 M(-19.1%) |
| Sep 2021 | - | $5.96 M(-12.3%) |
| Jun 2021 | - | $6.80 M(-12.2%) |
| Mar 2021 | - | $7.74 M(+52.7%) |
| Dec 2020 | $5.07 M(+95.1%) | $5.07 M(+371.0%) |
| Sep 2020 | - | $1.08 M(-39.3%) |
| Jun 2020 | - | $1.77 M(-18.8%) |
| Mar 2020 | - | $2.18 M(-15.9%) |
| Dec 2019 | $2.60 M(-39.2%) | $2.60 M(-12.7%) |
| Sep 2019 | - | $2.98 M(-16.5%) |
| Jun 2019 | - | $3.56 M(-8.5%) |
| Mar 2019 | - | $3.89 M(-8.9%) |
| Dec 2018 | $4.27 M(+227.3%) | $4.27 M(+1041.3%) |
| Sep 2018 | - | $374.40 K(-30.1%) |
| Jun 2018 | - | $536.00 K(-33.7%) |
| Mar 2018 | - | $808.00 K(-38.1%) |
| Dec 2017 | $1.31 M(+553.2%) | $1.31 M(-17.9%) |
| Sep 2017 | - | $1.59 M(-21.8%) |
| Jun 2017 | - | $2.03 M(+133.4%) |
| Mar 2017 | - | $870.90 K(+335.7%) |
| Dec 2016 | $199.90 K(+690.1%) | $199.90 K(-70.2%) |
| Sep 2016 | - | $669.80 K(+599.2%) |
| Jun 2016 | - | $95.80 K(-3.6%) |
| Mar 2016 | - | $99.40 K(+292.9%) |
| Dec 2015 | $25.30 K | $25.30 K(-88.4%) |
| Sep 2015 | - | $217.60 K(+72.0%) |
| Jun 2015 | - | $126.50 K(-9.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2015 | - | $140.10 K(+215.5%) |
| Dec 2014 | $44.40 K(-90.7%) | $44.40 K(+398.9%) |
| Sep 2014 | - | $8900.00(-80.9%) |
| Jun 2014 | - | $46.70 K(-59.5%) |
| Mar 2014 | - | $115.40 K(-75.7%) |
| Dec 2013 | $475.00 K(-71.3%) | $475.00 K(-39.9%) |
| Sep 2013 | - | $791.00 K(-26.4%) |
| Jun 2013 | - | $1.08 M(-21.8%) |
| Mar 2013 | - | $1.37 M(-16.9%) |
| Dec 2012 | $1.66 M(>+9900.0%) | $1.66 M(-12.0%) |
| Sep 2012 | - | $1.88 M(-13.6%) |
| Jun 2012 | - | $2.18 M(+3068.4%) |
| Mar 2012 | - | $68.70 K(+380.4%) |
| Dec 2011 | $14.30 K(-88.0%) | $14.30 K(-89.0%) |
| Sep 2011 | - | $130.00 K(+280.1%) |
| Jun 2011 | - | $34.20 K(-20.1%) |
| Mar 2011 | - | $42.80 K(-64.1%) |
| Dec 2010 | $119.10 K(-92.3%) | $119.10 K(-3.2%) |
| Sep 2010 | - | $123.10 K(+136.3%) |
| Jun 2010 | - | $52.10 K(-84.2%) |
| Mar 2010 | - | $329.10 K(-78.7%) |
| Dec 2009 | $1.54 M(>+9900.0%) | $1.54 M(+1298.6%) |
| Sep 2009 | - | $110.40 K(-33.4%) |
| Jun 2009 | - | $165.70 K(+90.9%) |
| Mar 2009 | - | $86.80 K(+734.6%) |
| Dec 2008 | $10.40 K(-98.0%) | $10.40 K(-56.3%) |
| Sep 2008 | - | $23.80 K(-88.2%) |
| Jun 2008 | - | $201.90 K(-38.7%) |
| Mar 2008 | - | $329.20 K(-35.2%) |
| Dec 2007 | $508.10 K(-25.2%) | $508.10 K(+309.4%) |
| Sep 2007 | - | $124.10 K(-36.3%) |
| Jun 2007 | - | $194.70 K(-63.7%) |
| Mar 2007 | - | $536.60 K(-21.0%) |
| Dec 2006 | $679.60 K(>+9900.0%) | $679.60 K(-6.1%) |
| Sep 2006 | - | $723.70 K(+24.0%) |
| Jun 2006 | - | $583.60 K(>+9900.0%) |
| Mar 2006 | - | $3000.00 |
| Dec 2005 | $4900.00 | - |
FAQ
- What is Lixte Biotechnology Holdings annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Lixte Biotechnology Holdings?
- What is Lixte Biotechnology Holdings annual cash & cash equivalents year-on-year change?
- What is Lixte Biotechnology Holdings quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Lixte Biotechnology Holdings?
- What is Lixte Biotechnology Holdings quarterly cash and cash equivalents year-on-year change?
What is Lixte Biotechnology Holdings annual cash & cash equivalents?
The current annual cash & cash equivalents of LIXT is $4.20 M
What is the all time high annual cash & cash equivalents for Lixte Biotechnology Holdings?
Lixte Biotechnology Holdings all-time high annual cash & cash equivalents is $5.35 M
What is Lixte Biotechnology Holdings annual cash & cash equivalents year-on-year change?
Over the past year, LIXT annual cash & cash equivalents has changed by -$1.15 M (-21.48%)
What is Lixte Biotechnology Holdings quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of LIXT is $1.64 M
What is the all time high quarterly cash and cash equivalents for Lixte Biotechnology Holdings?
Lixte Biotechnology Holdings all-time high quarterly cash and cash equivalents is $7.74 M
What is Lixte Biotechnology Holdings quarterly cash and cash equivalents year-on-year change?
Over the past year, LIXT quarterly cash and cash equivalents has changed by -$957.60 K (-36.90%)